This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Standard treatment for brain ependymomas includes surgery followed by focal radiotherapy when resection is incomplete. The role of chemotherapy for recurrent unresectable anaplastic ependymomas previously treated with radiotherapy is unsettled.1 We report an adult patient with a recurrent and multifocal anaplastic brain ependymoma who responded to the association of tamoxifen and isotretinoin.
Patient.
A 39-year-old man developed severe headaches in June 1997. A brain CT and MRI disclosed the presence of mild hydrocephaly and a right bulboprotuberantial heterogeneous tumor which enhanced after contrast infusion. A ventriculoperitoneal derivation was performed followed by an incomplete resection of the tumor. Histologic analysis revealed an anaplastic ependymoma. Focal radiotherapy (60 Gy) using conventional 2-Gy fractions was delivered between August 12, 1997, and September 23, 1997. In June 1998, the patient had recurrent headache and altered equilibrium and an MRI showed a heterogeneous enhancing lesion at the lateral edge of the pons invading the fourth …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma
The prognostic impact of prior low grade histology in patients with anaplastic gliomas
Bevacizumab for recurrent malignant gliomas